Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma

Immune checkpoint therapy has resulted in minimal clinical response in many pediatric cancers. We sought to understand the influence of immune checkpoint inhibition using anti-PD-1 and anti-CTLA-4 antibodies individually, in combination, and after chemotherapy on immune responses in minimal and esta...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncoimmunology
Asıl Yazarlar: Shirinbak, Soheila, Chan, Randall Y., Shahani, Shilpa, Muthugounder, Sakunthala, Kennedy, Rebekah, Hung, Long T., Fernandez, G. Esteban, Hadjidaniel, Michael D., Moghimi, Babak, Sheard, Michael A., Epstein, Alan L., Fabbri, Muller, Shimada, Hiroyuki, Asgharzadeh, Shahab
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2021
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7801125/
https://ncbi.nlm.nih.gov/pubmed/33489468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1838140
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller